NCT06824415

Brief Summary

The goal of this study is to establish the feasibility, tolerability, and preliminary efficacy of sleep-state transcranial magnetic stimulation (TMS) for enhancing plasticity in depression treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
23mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
May 2025May 2028

First Submitted

Initial submission to the registry

February 7, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 13, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2028

Last Updated

June 23, 2026

Status Verified

June 1, 2026

Enrollment Period

3.1 years

First QC Date

February 7, 2025

Last Update Submit

June 18, 2026

Conditions

Keywords

sleeptmseegiTBSreal-timeclosed-loopNREMsleep spindleslow oscillations

Outcome Measures

Primary Outcomes (6)

  • Change in Baseline TMS-EEG after iTBS

    Changes in Early Local TMS-Evoked Potentials (EL-TEP) following 3 minutes of either active or sham iTBS in each session to assess cortical excitability and plasticity measures. 1\) tbs; 2) sleep (cortical excitability and plasticity measures) in both active and sham.

    Baseline, end of iTBS (3 minutes)

  • Change in Baseline TMS-EEG after NREM Sleep

    Changes in Early Local TMS-Evoked Potentials (EL-TEP) following 3 hours of NREM sleep in each session to assess cortical excitability and plasticity measures.

    Baseline, end of sleep stage (3 hours)

  • Change in N-back Accuracy Performance

    N-back task (15-min) measures working memory performance and accuracy will be determined by the number of correct responses to the stimulus. Change in accuracy performance will be assessed before and after NREM sleep.

    Baseline, end of sleep stage (3 hours)

  • Change in N-back Reaction Time Performance

    N-back task (15-min) measures working memory performance and reaction time will be determined by the time it takes for the participant to respond to the stimulus. Change in reaction time performance will be assessed before and after NREM sleep.

    Baseline, end of sleep stage (3 hours)

  • Change in MSIT Accuracy Performance

    Multi-source Interference Task (MSIT; 15-min) measures cognitive control performance and accuracy will be determined by the number of correct responses to the stimulus. Change in accuracy performance will be assessed before and after NREM sleep.

    Baseline, end of sleep stage (3 hours)

  • Change in MSIT Reaction Time Performance

    Multi-source Interference Task (MSIT; 15-min) measures cognitive control performance and reaction time will be determined by the time it takes for the participant to respond to the stimulus. Change in reaction time performance will be assessed before and after NREM sleep.

    Baseline, end of sleep stage (3 hours)

Secondary Outcomes (4)

  • Changes in Pittsburgh Sleep Quality Index (PSQI) Scores

    After each sleep session (3 hours)

  • Changes in Treatment Tolerability

    After each sleep session (3 hours)

  • Change in EEG Spectral Power and Phase Measures

    Baseline, end of sleep stage (3 hours)

  • Change in Functional Connectivity Measures

    Baseline, end of sleep stage (3 hours)

Study Arms (2)

Active TMS, Sham TMS

EXPERIMENTAL

Participants will receive 2 sessions of Transcranial Magnetic Stimulation (TMS) delivered using standard intermittent theta-burst (iTBS) parameters (600 pulses, 3 min, 120% rMT). Participants will receive, on separate sessions, either active or sham iTBS delivered during wakefulness and/or NREM sleep stages while recording with Electroencephalography (EEG). Participants will perform the N-back task and Multi-source Interference Task (MSIT) during each session to measure working memory and cognitive control performance.

Device: TMS

Sham TMS, Active TMS

EXPERIMENTAL

Participants will receive 2 sessions of Transcranial Magnetic Stimulation (TMS) delivered during using standard intermittent theta-burst (iTBS) parameters (600 pulses, 3 min, 120% rMT). Participants will receive, on separate sessions, either active or sham iTBS delivered during wakefulness and/or NREM sleep stages while recording with Electroencephalography (EEG). Participants will perform the N-back task and Multi-source Interference Task (MSIT) during each session to measure working memory and cognitive control performance.

Device: TMS

Interventions

TMSDEVICE

Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.

Active TMS, Sham TMSSham TMS, Active TMS

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults ages 18-65 years
  • Current Major Depressive Disorder (MDD) diagnosis
  • Failed ≥1 antidepressant medication
  • Moderate-to-severe depression
  • Stable antidepressant medication dose for ≥ 6 weeks prior to enrollment
  • Healthy control participants are adults ages 18-65 years without current MDD symptoms, not taking antidepressant or antipsychotic medications, and without major psychiatric, neurological, substance use, medical conditions affecting brain function, or TMS/MRI contraindications.

You may not qualify if:

  • Intellectual disability
  • Significant head injury/neurological disorder
  • Pregnancy or postpartum
  • TMS/MRI contraindications
  • Active substance use/suicidal ideation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94305, United States

RECRUITING

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Study Officials

  • Umair Hassan, PhD

    Stanford University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Postdoctoral Researcher in Department of Psychiatry and Behavioral Sciences

Study Record Dates

First Submitted

February 7, 2025

First Posted

February 13, 2025

Study Start

May 1, 2025

Primary Completion (Estimated)

May 30, 2028

Study Completion (Estimated)

May 30, 2028

Last Updated

June 23, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Locations